ClinicalTrials.gg

Program

TQB3019

A development code. Also written as “TQB3019 capsules”.

In Sino Biopharmaceutical's pipeline, BTK PROTAC. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 1, since Apr 15, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since Apr 15, 2025Apr 15, 2025Dec 2027phase 1 · NCT06943677
  • Named in Sino Biopharmaceutical’s own pipeline as TQB3019, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 15, 2025First study: phase 1 study in Advanced Malignant CancerFirst studyNCT06943677 · 80 planned · China

Ahead

  1. Dec 2027Primary completion: phase 1 study in Advanced Malignant CancerNCT06943677

TargetBeta

“BTK PROTAC”the company's pipeline, read by Claude · source

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06943677Advanced Malignant Cancer · China1RecruitingDec 202780

How it is read

Names in the registry

  • “TQB3019 capsules”, 1 entry

Codes read as this program: TQB3019.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.